Finally, we observed that captopril and losartan, an inhibitor of AGTR1, reverses the cPLS (Figure 1, F–H, and Supplemental Table 2), confirming that the Ang/ACE/AGTR1 pathway is a mediator of the poor-prognosis PLS associated with poor survival and high HCC risk in patients (6–12). This evidence concerns the gene ACE and hepatocellular carcinoma.